[A20-04] Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65
Last updated 20.03.2020
Commission awarded on 07.01.2020 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Cystic fibrosis (CF) in patients aged 6 years and older and weighing 25 kg or more who have a G551D mutation in the CFTR gene
Conclusion of dossier assessment A19-65 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-65||Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.